welcome to neurology live®Friday 5! The staff puts together five highlights each week. neurology live®From newsworthy research findings and FDA actions, to expert interviews and peer-to-peer panel discussions on neurology.
1: Five FDA Pending Approvals in Neurology to Watch in 2023
Several therapeutic approvals are slated for 2023, ranging from movement disorders, neuromuscular, headache and migraine, to sleep disorders neurological specialties. Keeping up with the latest approvals can be difficult because of what is happening. Let’s take a look at the five most anticipated pending FDA approvals scheduled for 2023 that neurology researchers and clinicians should be watching.
2: peer exchange: Alzheimer’s Disease Treatment Pipeline
in episode 12 of this peer exchangeA panel of dementia experts discusses drug candidates and various mechanisms of action currently being evaluated for Alzheimer’s disease.of neurology live® Series Panel Features Marwan Sabbagh, MD; Alireza Atri, MD, PhD. Sharon Cohen, MD, FRCPC; and Eric McDade, DO.
3: NeuroVoices: Darin Okuda, MD, FAAN, FANA, Early detection of RIS and importance of ARISE research results
In the latest edition of our in-depth Q&A series, the director of the Neuroinnovation and Multiple Sclerosis and Neuroimmunoimaging Program at UT Southwestern Medical Center discusses the promising future of early-stage treatment of radiologically isolated syndromes. provided insight.
4: Episode 81: Robert Hauser, MD on PD Care and IPX203
in episode 81 of neurology live®mind moment of® The podcast features an exclusive interview with Robert Hauser, MD, Director of the Center for Parkinson’s Disease and Movement Disorders at the University of South Florida. He spoke about the current state of Parkinson’s disease treatment, some of the lingering challenges in day-to-day management, and the potential for novel agents in development such as IPX203.
5: MDA focuses on better access for patients with neuromuscular disease: Paul Melmeyer
Ahead of the 2023 MDA Conference March 19-22, 2023 in Dallas, Texas, the Muscular Dystrophy Association’s Vice President of Public Policy and Advocacy outlined the current state and need for access. There is a growing number of advocates for neuromuscular disease. [WATCH TIME: 14 minutes]
—————————————————
Nominated for Multiple Sclerosis Giant® it is open! This premier neuroscience awards program honors pioneers, innovators, and future generations of leaders for their outstanding work in multiple sclerosis. Nominations close on January 31, 2023.
Nominated: neurologylive.com/Giants-of-MS
